Immunotherapy
"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Descriptor ID |
D007167
|
MeSH Number(s) |
E02.095.465.425
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 | 1996 | 2 | 0 | 2 | 1997 | 2 | 2 | 4 | 1998 | 0 | 1 | 1 | 1999 | 2 | 3 | 5 | 2000 | 1 | 0 | 1 | 2002 | 2 | 3 | 5 | 2003 | 4 | 3 | 7 | 2004 | 1 | 2 | 3 | 2005 | 1 | 2 | 3 | 2006 | 7 | 5 | 12 | 2007 | 1 | 4 | 5 | 2008 | 11 | 2 | 13 | 2009 | 5 | 4 | 9 | 2010 | 6 | 6 | 12 | 2011 | 4 | 5 | 9 | 2012 | 6 | 2 | 8 | 2013 | 8 | 6 | 14 | 2014 | 11 | 5 | 16 | 2015 | 14 | 11 | 25 | 2016 | 10 | 6 | 16 | 2017 | 17 | 7 | 24 | 2018 | 14 | 14 | 28 | 2019 | 20 | 13 | 33 | 2020 | 21 | 23 | 44 | 2021 | 17 | 24 | 41 | 2022 | 4 | 21 | 25 | 2023 | 2 | 24 | 26 | 2024 | 8 | 15 | 23 | 2025 | 5 | 3 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Guo AA, Knapp MP, Evans JK, Faucheux AT, Price SN, Klepin HD, Levine B, Quattlebaum A, Bloomer C, Khoury L, Hunting JC, Elko CA, Olson E, Lycan TW. Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy. Future Oncol. 2025 Jun; 21(14):1787-1796.
-
Goff SL, Rosenberg SA. Tumor-infiltrating lymphocyte immunotherapy comes of age: a journey of development in the Surgery Branch, NCI. J Immunother Cancer. 2025 Apr 09; 13(4).
-
Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos MG, Assad N, Batist G, Bommareddy PK, Bonilla DL, Borchers CH, Church SE, Ciliberto G, Cogdill AP, Fattore L, Hacohen N, Haris M, Lacasse V, Lie WR, Mehta A, Ruella M, Sater HA, Spatz A, Taouli B, Tarhoni I, Gonzalez-Kozlova E, Tirosh I, Wang X, Gnjatic S. The Society for Immunotherapy of Cancer Perspective on Tissue-Based Technologies for Immuno-Oncology Biomarker Discovery and Application. Clin Cancer Res. 2025 Feb 03; 31(3):439-456.
-
Hunting JC, Price SN, Faucheux AT, Olson E, Elko CA, Quattlebaum A, Ruiz J, Lycan TW. Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study. Immunotherapy. 2025 01; 17(1):19-24.
-
Cogswell PM, Andrews TJ, Barakos JA, Barkhof F, Bash S, Benayoun MD, Chiang GC, Franceschi AM, Jack CR, Pillai JJ, Poussaint TY, Raji CA, Ramanan VK, Tanabe J, Tanenbaum L, Whitlow CT, Yu FF, Zaharchuk G, Zeinah M, Benzinger TS. Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities. AJNR Am J Neuroradiol. 2025 Jan 08; 46(1):24-32.
-
Gadwa J, Yu J, Piper M, Knitz MW, Darragh LB, Olimpo N, Corbo S, Beynor JI, Neupert B, Nguyen AT, Hodgson C, Nguyen D, Abdelazeem KN, Saviola A, Pousse L, Bransi A, Pincha M, Klein C, Amann M, Karam SD. Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment. J Immunother Cancer. 2025 Jan 07; 13(1).
-
Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, Balmanoukian AS, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher GA, Schmidt M, Schuler M, Sullivan RJ, Burris HA, Galvao V, Henick BS, Dirix L, Jaeger D, Ott PA, Wong KM, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner RS, Rittmeyer A, Laurie SA, Gort E, Aljumaily R, Melero I, Sabado RL, Rhee I, Mancuso MR, Muller L, Fine GD, Yadav M, Kim L, Leveque VJP, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao GK, Low DW, Petry C, Lo AA, Schartner JM, Delamarre L, Mellman I, L?wer M, M?ller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, L?rks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kr?ner C, Tadmor AD, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn AN, Sahin U, T?reci ?, Camidge DR. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med. 2025 Jan; 31(1):152-164.
-
Fathi Kazerooni A, Kraya A, Rathi KS, Kim MC, Vossough A, Khalili N, Familiar AM, Gandhi D, Khalili N, Kesherwani V, Haldar D, Anderson H, Jin R, Mahtabfar A, Bagheri S, Guo Y, Li Q, Huang X, Zhu Y, Sickler A, Lueder MR, Phul S, Koptyra M, Storm PB, Ware JB, Song Y, Davatzikos C, Foster JB, Mueller S, Fisher MJ, Resnick AC, Nabavizadeh A. Multiparametric MRI along with machine learning predicts prognosis and treatment response in pediatric low-grade glioma. Nat Commun. 2025 Jan 02; 16(1):340.
-
Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E, Woroniecka K, Finlay JB, Ayasoufi K, Fecci PE. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity. 2025 Jan 14; 58(1):232-246.e6.
-
Balestra T, Niswander LM, Bagashev A, Loftus JP, Ross SL, Chen RK, McClellan SM, Junco JJ, B?rcenas L?pez DA, Rabin KR, Fry TJ, Tasian SK. Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025 Mar; 39(3):555-567.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|